0000950123-11-086141.txt : 20110922 0000950123-11-086141.hdr.sgml : 20110922 20110922171841 ACCESSION NUMBER: 0000950123-11-086141 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110916 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20110922 DATE AS OF CHANGE: 20110922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OXIGENE INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21990 FILM NUMBER: 111103711 BUSINESS ADDRESS: STREET 1: 701 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 701 GATEWAY BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 b88341e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 16, 2011
 
OXiGENE, Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  0-21990
(Commission File Number) 		  13-3679168
(IRS Employer
Identification No.)
     
701 Gateway Boulevard, Suite 210, South
San Francisco, CA
(Address of principal executive offices) 		  94080 (Zip
Code)
Registrant’s telephone number, including area code: (650) 635-7000
 
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 7.01.   Regulation FD Disclosure.
OXiGENE Regains Compliance With NASDAQ Listing Requirements.
OXiGENE, Inc. today announced that it has received a letter from the NASDAQ Capital Market confirming that, with the appointment of Gerald McMahon, Ph.D. to the Company’s board of directors and audit committee, as detailed in the Company’s Form 8-K dated September 2, 2011, NASDAQ staff has determined that the Company complies with Listing Rules 5605(b)(1) and 5605(c)(2) requiring the Company to have a majority of independent directors on its board and at least three independent directors on its audit committee for continued listing on the NASDAQ Capital Market, and this matter is now closed.
The information contained in this Current Report on Form 8—K is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  OXiGENE, Inc.
(Registrant)
 		  
September 22, 2011  /s/ PETER J. LANGECKER, M.D., Ph.D.    
(Date)  Peter J. Langecker, M.D., Ph.D.   
  CEO